Iconix Signs Chemogenomics Agreement with Taisho | GenomeWeb

NEW YORK, June 15 (GenomeWeb News) - Iconix Pharmaceuticals will perform chemogenomics profiling and analysis services for Taisho Pharmaceutical of Japan, Mountain View, Calif.-based Iconix said today.

 

Under the agreement, Taisho will apply Iconix's DrugMatrix platform, a chemogenomics database, to help it select and optimize drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.